Back

Targeting Transferrin Receptor to Transport Antisense Oligonucleotides Across the Blood-Brain Barrier

Barker, S. J.; Thayer, M. B.; Kim, C.; Tatarakis, D.; Simon, M.; Dial, R. L.; Nilewski, L.; Wells, R. C.; Zhou, Y.; Afetian, M.; Chappell, A.; Chew, K. S.; Chow, J.; Clemens, A.; Discenza, C. B.; Dugas, J. C.; Dwyer, C.; Earr, T.; Ha, C.; Huynh, D.; Jayaraman, S.; Kwan, W.; Mahon, C.; Pizzo, M.; Roche, E.; Sanders, L.; Stergioulis, A.; Tong, R.; Tran, H.; Zuchero, J.; Estrada, A. A.; Gadkar, K.; Koth, C. M.; Sanchez, P. E.; Thorne, R. G.; Watts, R. J.; Sandmann, T.; Kane, L. A.; Rigo, F.; Dennis, M. S.; Lewcock, J. W.; DeVos, S. L.

2023-04-28 neuroscience
10.1101/2023.04.25.538145 bioRxiv
Show abstract

Antisense oligonucleotides (ASO) are promising therapies for neurological disorders, though they are unable to cross the blood-brain barrier (BBB) and must be delivered directly to the central nervous system (CNS). Here, we use a human transferrin receptor (TfR)-binding molecule to transport ASO across the BBB in mice and non-human primates, termed oligonucleotide transport vehicle (OTV). Systemically delivered OTV drives significant, cumulative, and sustained knockdown of the ASO target across multiple CNS regions and all major cell types. Further, systemic OTV delivery enables more uniform ASO biodistribution and knockdown compared to two other clinically relevant ASO delivery routes: a standard, high affinity TfR antibody, or direct ASO delivery to the CSF. Together, our data support systemically delivered OTV as a potential therapeutic platform for neurological disorders. One-Sentence SummarySystemically dosed OTV delivered via TfR1 targeting shows widespread and cumulative target knockdown in the mouse and NHP CNS.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 4%
27.5%
Similar papers in this journal
2
Molecular Therapy
○ 81 papers in training set
Top 0.2%
8.2%
Similar papers in this journal
3
Science Advances
● 1243 papers in training set
Top 3%
7.0%
Similar papers in this journal
4
eLife
● 5828 papers in training set
Top 29%
4.2%
Similar papers in this journal
5
Neuron
○ 337 papers in training set
Top 2%
3.3%
Similar papers in this journal
50% of probability mass above
6
Cell Reports
○ 1498 papers in training set
Top 14%
2.7%
7
Nucleic Acids Research
◐ 1281 papers in training set
Top 6%
2.7%
8
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 19%
2.7%
9
Advanced Science
○ 286 papers in training set
Top 3%
2.5%
10
Molecular Psychiatry
○ 282 papers in training set
Top 3%
2.5%
11
Journal of Controlled Release
○ 44 papers in training set
Top 0.4%
2.2%
12
Nature Biotechnology
○ 172 papers in training set
Top 2%
2.0%
13
Nature Biomedical Engineering
○ 47 papers in training set
Top 0.7%
2.0%
14
Science
● 477 papers in training set
Top 6%
1.6%
15
PLOS ONE
● 5266 papers in training set
Top 50%
1.4%
16
Communications Biology
○ 993 papers in training set
Top 20%
1.2%
17
Molecular Therapy Nucleic Acids
○ 39 papers in training set
Top 0.6%
1.2%
18
Science Translational Medicine
● 127 papers in training set
Top 3%
1.1%
19
Scientific Reports
○ 3612 papers in training set
Top 66%
1.1%
20
Nature Methods
○ 385 papers in training set
Top 6%
0.9%
21
Biomaterials
○ 84 papers in training set
Top 1%
0.9%
22
Molecular Metabolism
○ 112 papers in training set
Top 2%
0.6%
23
JCI Insight
● 277 papers in training set
Top 8%
0.6%
24
Alzheimer's & Dementia
177 papers in training set
Top 2%
0.6%
25
Nature Neuroscience
○ 252 papers in training set
Top 5%
0.6%
26
iScience
○ 1154 papers in training set
Top 39%
0.6%
27
Neuropsychopharmacology
○ 153 papers in training set
Top 3%
0.6%
28
Journal of Experimental Medicine
● 119 papers in training set
Top 3%
0.6%
29
ACS Chemical Neuroscience
● 67 papers in training set
Top 2%
0.6%
30
Advanced Healthcare Materials
○ 85 papers in training set
Top 1%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.